Acotec Scientific Holdings Ltd. has announced that it has received registration approval from the PRC National Medical Products Administration for its Vertebral Artery Paclitaxel-coated Balloon Dilatation Catheter, AcoArt Verbena®. This device is intended for percutaneous transluminal angioplasty in symptomatic patients with significant stenosis at the origin of the vertebral artery. The approval marks a significant step in advancing treatment for vertebral artery stenosis, promising a new era of "Leave Nothing Behind" in medical procedures. The clinical trials showed that AcoArt Verbena® had a restenosis rate of 13.04% at 12 months post-procedure, significantly lower than the control group's rate of 37.31%. This approval is a key development for Acotec Scientific Holdings Ltd. as it plans to commence marketing efforts in the PRC market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。